NEU 0.00% $19.97 neuren pharmaceuticals limited

Share Price, page-2491

  1. 5,867 Posts.
    lightbulb Created with Sketch. 17381
    I really don’t know how important this would be.

    I do know that Neuren filed an international patent application two years ago for new compositions and manufacturing methods which allow substantially larger quantities of trofinetide to be produced in a way that is more commercially beneficial.

    The inventors listed on this patent are drawn from Neuren, Acadia and PeptiSyntha SA Belgium/ Corden Pharma Switzerland (Corden is the parent company of PeptiSyntha). So Corden is at least a conveniently located manufacturer for any European pharma.

    Under the terms of the licence, Acadia was granted a non-exclusive licence to have trofinetide manufactured outside of North America.

    https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021026066&_cid=P11-L9FI68-39396-4
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.